Factors Affecting the Price of Vocabria

As a long-acting anti-HIV drug, cabotegravir has been approved in multiple countries and regions, mainly for the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP): In 2021, the U.S. FDA approved its long-acting injection (in combination with rilpivirine) for the maintenance treatment of HIV-1 infection, and its long-acting injection as a single agent for PrEP. Regions such as the European Union, Canada, and Australia have also granted approval, with indications basically consistent with those in the United States.